Eduardo Alegría-Ezquerra , Eduardo Alegría-Barrero , Ana Alegría-Barrero
{"title":"欧洲血脂异常指南。优点和缺点","authors":"Eduardo Alegría-Ezquerra , Eduardo Alegría-Barrero , Ana Alegría-Barrero","doi":"10.1016/S1131-3587(15)70119-6","DOIUrl":null,"url":null,"abstract":"<div><p>The joint guidelines of the European Society of Cardiology and the European Atherosclerosis Society on the management of dyslipidemia include a number of interesting clinical features: risk stratification provides the basis for selecting the type and intensity of lipid-lowering treatment; the principal therapeutic target is the low-density lipoprotein cholesterol level; the precise treatment target for this parameter depends on the level of risk (<70<!--> <!-->mg/dl for very-high-risk patients and <100<!--> <!-->mg/dl for high-risk patients); potent statins, given at a high dose, are the drugs of choice for achieving these goals; and particular recommendations must be followed for a number of common clinical scenarios: e.g. the elderly, women, patients with chronic kidney disease and secondary prevention.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(15)70119-6","citationCount":"0","resultStr":"{\"title\":\"La guía europea de dislipemia. Fortalezas y debilidades\",\"authors\":\"Eduardo Alegría-Ezquerra , Eduardo Alegría-Barrero , Ana Alegría-Barrero\",\"doi\":\"10.1016/S1131-3587(15)70119-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The joint guidelines of the European Society of Cardiology and the European Atherosclerosis Society on the management of dyslipidemia include a number of interesting clinical features: risk stratification provides the basis for selecting the type and intensity of lipid-lowering treatment; the principal therapeutic target is the low-density lipoprotein cholesterol level; the precise treatment target for this parameter depends on the level of risk (<70<!--> <!-->mg/dl for very-high-risk patients and <100<!--> <!-->mg/dl for high-risk patients); potent statins, given at a high dose, are the drugs of choice for achieving these goals; and particular recommendations must be followed for a number of common clinical scenarios: e.g. the elderly, women, patients with chronic kidney disease and secondary prevention.</p></div>\",\"PeriodicalId\":34926,\"journal\":{\"name\":\"Revista Espanola de Cardiologia Suplementos\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/S1131-3587(15)70119-6\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Espanola de Cardiologia Suplementos\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1131358715701196\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola de Cardiologia Suplementos","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1131358715701196","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
La guía europea de dislipemia. Fortalezas y debilidades
The joint guidelines of the European Society of Cardiology and the European Atherosclerosis Society on the management of dyslipidemia include a number of interesting clinical features: risk stratification provides the basis for selecting the type and intensity of lipid-lowering treatment; the principal therapeutic target is the low-density lipoprotein cholesterol level; the precise treatment target for this parameter depends on the level of risk (<70 mg/dl for very-high-risk patients and <100 mg/dl for high-risk patients); potent statins, given at a high dose, are the drugs of choice for achieving these goals; and particular recommendations must be followed for a number of common clinical scenarios: e.g. the elderly, women, patients with chronic kidney disease and secondary prevention.
期刊介绍:
Revista Española de Cardiología, is an international scientific journal dealing with cardiovascular medicine. Revista Española de Cardiología, the official publication of the Spanish Society of Cardiology, publishes research articles related to cardiovascular diseases. Articles are published in Spanish for the paper edition and in both Spanish and English in the electronic edition, which is available on the Internet. Regular sections include original articles reporting clinical or basic research, brief reports, review articles, editorials and letters to the Editor.